Keros Therapeutics Inc

KROS

17.570USD

+0.330+1.91%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Keros Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

28 / 392

Overall Ranking

123 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Keros Therapeutics Inc Highlights

StrengthsRisks

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.55M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.55M.

Overvalued

The company’s latest PE is 11.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 29.79M shares, decreasing 50.36% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.96K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

23.500

Target Price

+30.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Keros Therapeutics Inc is 8.90, ranking 22 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 14.26M, representing a year-over-year increase of 3575.77%, while its net profit experienced a year-over-year increase of 86.25%.

Score

Industry at a Glance

Previous score

8.90

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Keros Therapeutics Inc is 7.77, ranking 80 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 11.03, which is 307.08% below the recent high of 44.91 and 1106.01% above the recent low of -110.99.

Score

Industry at a Glance

Previous score

7.77

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Keros Therapeutics Inc is 7.80, ranking 267 out of 392 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 35.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

7.80

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Keros Therapeutics Inc is 5.69, ranking 300 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.27 and the support level at 16.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.50

Change

0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Keros Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 97.77%, representing a quarter-over-quarter decrease of 21.22%. The largest institutional shareholder is The Vanguard, holding a total of 1.52M shares, representing 4.99% of shares outstanding, with 20.99% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Madison Avenue Partners LP

2.71M

+0.62%

Tang Capital Management, LLC

2.42M

+70.47%

BlackRock Institutional Trust Company, N.A.

2.36M

-1.47%

ExodusPoint Capital Management, LP

1.91M

+8204.24%

D. E. Shaw & Co., L.P.

1.55M

+16.11%

The Vanguard Group, Inc.

Star Investors

2.71M

+3.33%

State Street Investment Management (US)

1.30M

-5.87%

Nantahala Capital Management, LLC

1.23M

-23.91%

Goldman Sachs Asset Management, L.P.

874.78K

+89.25%

Logos Global Management LP

850.00K

-57.50%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Keros Therapeutics Inc is 5.98, ranking 32 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.85. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Keros Therapeutics Inc

KROS

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment